» Portfolio News

10.02.17

NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

Weiterlesen...

04.01.17

NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Weiterlesen...

15.12.16

NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda® (Pembrolizumab) in panacreatic and colorectal Cancer

Weiterlesen...

05.12.16

NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies 

Weiterlesen...

30.11.16

NOXXON Pharma N.V.: First Berlin startet Coverage mit Kaufempfehlung, 

Kursziel EUR 40,00 

Weiterlesen...

04.01.17 - NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion


NOXXON continues transition to clincal oncology company

 


Berlin, Germany, January 04, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion.

 

 

NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer® technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.

 

 

“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.” commented Aram Mangasarian, CEO of NOXXON.